Blockade of CD200 in the presence or absence of antibody effector function: Implications for anti-CD200 therapy

Journal of Immunology

Volumn 180, Issue 2, 2008, Pages 699-705

  Kretz Romme, Anke ^a   Qin, Fenghua ^a   Dakappagari, Naveen ^a   Cofiell, Roxanne ^b   Faas, Susan J ^b   Bowdish, Katherine S ^a  

^a Alexion Antibody Technologies Inc   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CHB7 G1; MONOCLONAL ANTIBODY CHB7 G2G4; MONOCLONAL ANTIBODY HB7V2 G1; MONOCLONAL ANTIBODY HB7V2 G2G4; UNCLASSIFIED DRUG; ANTIGENS, CD200; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CD3+ T LYMPHOCYTE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; EFFECTOR CELL; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR VOLUME; UPREGULATION; XENOGRAFT; ANIMAL; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; MOUSE STRAIN; NEOPLASM; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; MICE; MICE, INBRED STRAINS; NEOPLASMS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40449088359     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.2.699     Document Type: Article

References (37)

1. Hoek, R. M., S. R. Ruuls, C. A. Murphy, G. J. Wright, R. Goddard, S. M. Zurawski, B. Blom, M. E. Homola, W. J. Streit, M. H. Brown, et al. 2000. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290: 1768-1771.
2. Gorczynski, R. M., M. S. Cattral, Z. Chen, J. Hu, J. Lei, W. P. Min, G. Yu, and J. Ni. 1999. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J. Immunol. 163: 1654-1660.
3. McWhirter, J. R., A. Kretz-Rommel, A. Saven, T. Maruyama, K. N. Potter, C. I. Mockridge, E. P. Ravey, F. Qin, and K. S. Bowdish. 2006. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. USA 103: 1041-1046.
4. Moreaux, J., D. Hose, T. Reme, E. Jourdan, M. Hundemer, E. Legouffe, P. Moine, P. Bourin, M. Moos, J. Corre, et al. 2006. CD200 is a new prognostic factor in multiple myeloma. Blood 108: 4194-4197.
5. Tonks, A., R. Hills, P. White, B. Rosie, K. I. Mills, A. K. Burnett, and R. L. Darley. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21: 566-568.
6. Barclay, A. N., M. J. Clark, and G. W. McCaughan. 1986. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem. Soc. Symp. 51: 149-157.
7. Wright, G. J., M. Jones, M. J. Puklavec, M. H. Brown, and A. N. Barclay. 2001. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102: 173-179.
8. Kretz-Rommel, A., F. Qin, N. Dakappagari, E. P. Ravey, J. McWhirter, D. Oltean, S. Frederickson, T. Maruyama, M. A. Wild, M. J. Nolan, et al. 2007. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol. 178: 5595-5605.
9. Grillo-Lopez, A. J., C. A. White, C. Varns, D. Shen, A. Wei, A. McClure, and B. K. Dallaire. 1999. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26: 66-73.
10. Hale, G., M. J. Dyer, M. R. Clark, J. M. Phillips, R. Marcus, L. Riechmann, G. Winter, and H. Waldmann. 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394-1399.
11. Leyland-Jones, B. 2002. Trastuzumab therapy for the metastatic patient: does the primary match? Ann. Oncol. 13: 993-994.
12. Cilley, J. C., K. Barfi, A. B. Benson, III, and M. F. Mulcahy. 2007. Bevacizumab in the treatment of colorectal cancer. Expert. Opin. Biol. Ther. 7: 739-749.
13. Zhang, W., M. Gordon, and H. J. Lenz. 2006. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann. Med. 38: 545-551.
14. Cartron, G., H. Watier, J. Golay, and P. Solal-Celigny. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642.
15. Nahta, R., and F. J. Esteva. 2007. Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643.
16. Epstein, M. A., B. G. Achong, Y. M. Barr, B. Zajac, G. Henle, and W. Henle. 1966. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J. Natl. Cancer Inst. 37: 547-559.
17. Mueller, J. P., M. A. Giannoni, S. L. Hartman, E. A. Elliott, S. P. Squinto, L. A. Matis, and M. J. Evans. 1997. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol. Immunol. 34: 441-452.
18. Canfield, S. M., and S. L. Morrison. 1991. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173: 1483-1491.
19. Niwa, R., A. Natsume, A. Uehara, M. Wakitani, S. Iida, K. Uchida, M. Satoh, and K. Shitara. 2005. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306: 151-160.
20. Dall'Acqua, W. F., K. E. Cook, M. M. Damschroder, R. M. Woods, and H. Wu. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177: 1129-1138.
21. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
22. Siberil, S., C. A. Dutertre, W. H. Fridman, and J. L. Teillaud. 2007. FcγR: The key to optimize therapeutic antibodies? Crit. Rev. Oncol. Hematol. 62: 26-33.
23. Dall'Ozzo, S., S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, and G. Thibault. 2004. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 64: 4664-4669.
24. Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89: 4285-4289.
25. Mendelsohn, J., and J. Baselga. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
26. Vossen, A. C., G. J. Tibbe, M. J. Kroos, J. G. van de Winkel, R. Benner, and H. F. Savelkoul. 1995. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur. J. Immunol. 25: 1492-1496.
27. Tao, M. H., R. I. Smith, and S. L. Morrison. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178: 661-667.
28. Hillmen, P., C. Hall, J. C. Marsh, M. Elebute, M. P. Bombara, B. E. Petro, M. J. Cullen, S. J. Richards, S. A. Rollins, C. F. Mojcik, and R. P. Rother. 2004. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350: 552-559.
29. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
30. Hodi, F. S., M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100: 4712-4717.
31. Maker, A. V., G. Q. Phan, P. Attia, J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, L. R. Haworth, C. Levy, et al. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12: 1005-1016.
32. French, R. R., V. Y. Taraban, G. R. Crowther, T. F. Rowley, J. C. Gray, P. W. Johnson, A. L. Tutt, A. Al-Shamkhani, and M. J. Glennie. 2007. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109: 4810 - 4815.
33. Miller, R. E., J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch. 2002. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169: 1792-1800.
34. Curiel, T. J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. Krzysiek, K. L. Knutson, B. Daniel, M. C. Zimmermann, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9: 562-567.
35. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881.
36. Wang, H. Y., and R. F. Wang. 2007. Regulatory T cells and cancer. Curr. Opin. Immunol. 19: 217-223.
37. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4: 336-347.